A recent study investigated whether an increase in access to PrEP would increase the likelihood of adherence to the medication. Do you think this would work in your practice?
Some patients take PrEP medications for extended periods of time, as their HIV risk persists. Talk to your patients about Descovy for PrEP. This video is sponsored by Gilead Sciences, Inc.
For the first time, the US Preventive Services Task Force has made recommendations for all at-risk populations of HIV infection to receive PrEP therapy. To see which populations are included in this recommendation, read more.
A new study presented at AIDS 2018 shed light on the incidence of hepatitis C virus re-infection among men who have sex with men and were using pre-exposure prophylaxis. The findings may lead to better disease management.